Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

NJIT Membrane Separation Technologies Expert To Receive Upcoming Top Honor
Kamalesh Sirkar, PhD, distinguished professor of chemical engineering at NJIT, and internationally-renowned expert in membrane separation technologies will be the recipient of the NJIT Board of Overseers Excellence in Research Prize and Medal. The award presentation and lecture will take place Wednesday, Oct. 7, 2009, in Kupfrian Hall on the NJIT campus.
generic viagra online
Charities Launch Groundbreaking Research Cancer Centre In Newcastle, England
The opening of a unique centre will put Newcastle at the forefront of cancer research and bring benefits to patients in the North East.
News of the day
Gpx5: Sperm Shouldn't Leave The Testes Without This Protein
Joel Drevet and colleagues, at Clermont Universitç©, France, have identified a protein that helps protect immature mouse sperm after they have been released into a region of the testis known as the epididymis, which is where they undergo maturation. Although male mice lacking this protein, Gpx5, had normal looking sperm and were equally as efficient as normal male mice at fertilizing female mice, an increased incidence of miscarriages and fetal developmental defects were observed when normal female mice were mated with Gpx5-deficient males over 1 year old compared with normal male mice of the same age. Further analysis indicated that Gpx5 acts as an antioxidant in the epididymis, protecting the sperm from oxidative stress. As discussed by the authors, and, in an accompanying commentary, John Aitken, at the University of Newcastle, Australia, these data have immense clinical relevance as age-related DNA damage to human sperm has been associated with a range of adverse outcomes including decreased fertility, and increased rates of miscarriage and childhood disease.
Diagnostics

Unlikely Treatment Identified By BrainCells Neurogenesis Platform Improved Clinical Outcomes In Patients Suffering From Depression

BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). The data were presented at NCDEU 2009, a meeting co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology. Neurogenesis is the process by which pre-existing stem cells in the hippocampus of the adult brain produce new brain cells, including neurons. "Our study results provide the first prospective clinical validation of neurogenesis as a target for the treatment of mood disorders like depression, in contrast to the traditional focus on affecting serotonin function for antidepressant drug development," said lead investigator Maurizio Fava, M.D., vice chair, department of psychiatry at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Researchers have speculated that the brain"s ability to grow new brain cells may have an impact on depression, and we now know that we can stimulate the natural process of neurogenesis with a positive clinical impact on depression symptoms." "BCI-952 was selected by our proprietary platform for the compound"s neurogenic properties," said Jim Schoeneck, chief executive officer of BrainCells Inc. "The platform was able to identify the pathway, ratio of drug and dosing that shaped the clinical trial protocol, directing the first rational approach to drug development in the area of psychiatry." The double blind, placebo-controlled, randomized study evaluated the efficacy of BCI-952 for the treatment of MDD in 142 patients over a six-week period. Patients were randomized into one of three arms, BCI-952 (n=67), buspirone (n=34) or placebo (n=33). Co-primary endpoints were the Clinical Global Impression-Improvement (CGI-I) and the Quick Inventory of Depressive Symptomatology (QIDS SR-16). Secondary endpoints included the CGI-S, IDSC30 and HAMA. The data presented at the NCDEU meeting focused on the MITT population using both the LOCF and MMRM analyses for the co-primary endpoints. The CGI-I at week six demonstrated improvement relative to placebo using the MITT LOCF, MITT MMRM. The mean CGI-I scores were statistically significant relative to placebo using the MITT MMRM (p=0.046).The responders analysis for CGI-I (SCORE About BrainCells Inc. BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for small molecule therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of indications. BrainCells Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009